Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular amd

British Journal of Ophthalmology

Volumn 98, Issue 12, 2014, Pages 1636-1641

  Avery, Robert L ^a   Castellarin, Alessandro A ^a   Steinle, Nathan C ^a   Dhoot, Dilsher S ^a   Pieramici, Dante Joseph ^a   See, Robert ^a   Couvillion, Stephen ^a   Nasir, MA'An A ^a   Rabena, Melvin D ^a   Le, Kha ^b   Maia, Mauricio ^b   Visich, Jennifer E ^b  

^a California Retina Consultants   (United States)

^b GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; RANIBIZUMAB; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; HYBRID PROTEIN; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VEGFA PROTEIN, HUMAN;

AGE RELATED MACULAR DEGENERATION; ANIMAL CELL; ANTIANGIOGENIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; FEMALE; HUMAN; IC50; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM PLASMA CONCENTRATION; NONHUMAN; PROTEIN BLOOD LEVEL; SWINE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT OUTCOME; WET MACULAR DEGENERATION; AGED; ANTAGONISTS AND INHIBITORS; BIOAVAILABILITY; BLOOD; COMPARATIVE STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HALF LIFE TIME; INTRAVITREAL DRUG ADMINISTRATION; METABOLISM; PROSPECTIVE STUDY; TISSUE DISTRIBUTION; VITREOUS BODY;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BEVACIZUMAB; BIOLOGICAL AVAILABILITY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HALF-LIFE; HUMANS; INTRAVITREAL INJECTIONS; MALE; PROSPECTIVE STUDIES; RANIBIZUMAB; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; TISSUE DISTRIBUTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY; WET MACULAR DEGENERATION;

EID: 84911988207     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2014-305252     Document Type: Article

References (33)

1. Rothen M, Jablon E, Monares G, et al. Anti-macular degeneration agents. Ophthalmol Clin North Am 2005;18:561-7.
2. Avastin (bevacizumab) solution for intravenous infusion prescribing information. http://www.gene.com/download/pdf/avastin-prescribing.pdf (accessed 11 Mar 2014).
3. Lucentis (ranibizumab injection) intravitreal injection prescribing information. http:// www.gene.com/download/pdf/lucentis-prescribing.pdf (accessed 11 Mar 2014).
4. Xu L, Lu T, Tuomi L, et al. Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: a population approach. Invest Ophthalmol Vis Sci 2013;54:1616-24.
5. Ferrara N, Damico L, Shams N, et al. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2006;26:859-70.
6. Stewart MW. Aflibercept (VEGF-TRAP): the next anti-VEGF drug. Inflamm Allergy Drug Targets 2011;10:497-508.
7. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002;99:11393-8.
8. Chakravarthy U, Harding SP, Rogers CA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet 2013;382:1258-67.
9. Chakravarthy U, Harding SP, Rogers CA, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 2012;119:1399-411.
10. Kodjikian L, Souied EH, Mimoun G, et al . Ranibizumab versus bevacizumab for neovascular age-related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology 2013;120:2300-9.
11. Krebs I, Schmetterer L, Boltz A, et al. A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. Br J Ophthalmol 2013;97:266-71.
12. Martin DF, Maguire MG, Fine SL, et al .; Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012;119:1388-98.
13. Martin DF, Maguire MG, Ying GS, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897-908.
14. Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 2009;6:465-77.
15. Carneiro AM, Costa R, Falcao MS, et al. Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab. Acta Ophthalmol 2012;90:e25-30.
16. Gu X, Yu X, Dai H. Intravitreal Injection of ranibizumab for treatment of age-related macular degeneration: effects on serum VEGF concentration. Curr Eye Res 2014;39:518-21.
17. Matsuyama K, Ogata N, Matsuoka M, et al. Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab. Br J Ophthalmol 2010;94:1215-18.
18. Zehetner C, Kirchmair R, Huber S, et al. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema. Br J Ophthalmol 2013;97:454-9.
19. Harding SP. IVAN Outcomes [abstract]. Invest Ophthalmol Vis Sci 2013;54. ARVO E-Abstract.
20. Krohne TU, Liu Z, Holz FG, et al. Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans. Am J Ophthalmol 2012;154:682-6 e2.
21. Krohne TU, Eter N, Holz FG, et al. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol 2008;146:508-12.
22. Aguilar-Mahecha A, Kuzyk MA, Domanski D, et al. The effect of pre-analytical variability on the measurement of MRM-MS-based mid- to high-abundance plasma protein biomarkers and a panel of cytokines. PLoS ONE 2012;7:e38290.
23. Yu L, Liang XH, Ferrara N. Comparing protein VEGF inhibitors: in vitro biological studies. Biochem Biophys Res Commun 2011;408:276-81.
24. Ternant D, Paintaud G. Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins. Expert Opin Biol Ther 2005;5(Suppl 1):S37-47.
25. Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 2012;15:171-85.
26. Kim H, Robinson SB, Csaky KG. FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye. Mol Vis 2009;15:2803-12.
27. Bressler NM, Boyer DS, Williams DF, et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina 2012;32:1821-8.
28. Avery RL, Francom SF, Lai P, et al. Meta-analysis examining the systemic safety profile of intravitreal ranibizumab injections in AMD, RVO, and DME. Invest Ophthalmol Vis Sci 2013;54:ARVO E-Abstract 1535.
29. European Medicines Agency. EPAR: Eylea (afl ibercept) procedure no. EMEA/H/C/
30. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Public- assessment-report/human/002392/WC500135744.pdf (accessed 11 Mar 2014).
31. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006;113:1695 e1-15.
32. Bakbak B, Ozturk BT, Gonul S, et al . Comparison of the effect of unilateral intravitreal bevacizumab and ranibizumab injection on diabetic macular edema of the fellow eye. J Ocular Pharmacol Ther 2013;29:728-32.
33. Avery RL. What is the evidence for systemic effects of intravitreal anti-VEGF agents, and should we be concerned? Br J Ophthalmol 2014;98(Suppl 1):i7-10.